.
solid phase, two-site, immunoradiometric assays (m), similar to the one described first by us (13, 14) .
In this study we compared the first two commercial assays for Tg-a competitive-binding RIA by Nuclear Medical Systems (NMS) and the "CIS" mr-type assay-with each other and with the Tg assay developed at Stanford a few years ago (13). We studied the analytical and clinical performance of these assays and evaluated their clinical utility in the management of patients with thyroid cancer.
Materials and Methods

Procedures
For measurement of Tg in serum, we used the following assays. 
NMS
Measurement of anti-Tg autoantibodies
in sera. Anti-Tg was measured by a solid-phase, sandwich-type RIA (15) .
Assay Validation
The Tg standard preparations and the specificity of the antisera were examined by comparing the standard curve of each assay with (a) curves generated with serial dilutions of sera from thyroid-cancer patients that contained high concentrations of Tg, (b) with dose-response curves obtained by use of the Tg standard solutions of the other two methods, and (c) with dose-response curves produced by serial dilutions of the most concentrated standard of each method. Serial dilutions were made in serum from athyreotic patients (whose thyroids had been removed surgically) who were judged clinically to be disease free and who had no measurable Tg or anti-Tg. To rule out differences in the dilutions, we analyzed the same serial dilutions in parallel experiments, following the assay protocols exactly.
Analytical recovery studies involved adding Tg (20-100 ,ag/L, either the CIS or NMS standards) to serum specimens from thyroid-cancer patients with undetectable to moderately increased Tg (0-100 g/L)
concentrations. The same mixtures of various sera plus exogenous Tg were analyzed by all three assays and the recovery was calculated as follows: (Tgf0d -Tgedogefl0)
x lOO/Tg,,,d.
Intra-and inter-assay coefficients of variation were determined with three serum pools with Tg concentrations in the low, middle, and high assay range. Each pool was measured in at least eight replicates in one assay set-up and (in duplicate) in 10 consecutive assays.
The normal range for individuals with an intact thyroid is 40 pg/L in the Stanford assay (13) and (as suggested by the manufacturers) 60 g/L for the CIS and NMS assays, but these values cannot be applied to athyreotic patients. The reference values for thyroid-cancer patients were determined, retrospectively, in a group of more than 100 patients seen at Stanford during the past years by correlating results for Tg (generated with the Stanford assay) with all the relevant clinical data ( 
Patients
Group 1 consisted of 50 patients seen at the Stanford University Medical Center, whose history and extent of disease was known clinically, for correlation with Tg measurements. All of these patients had been treated for folliculax, papillary, or mixed papillary-follicular thyroid cancer.
Thirty-one had undergone total (or near-total) thyroidectomy followed by 131j ablation therapy; nine patients had subtotal thyroidectomy and ''i treatment; and four patients had total and six had subtotal thyroidectomy without
131J
All were receiving adequate T4 replacement and had normal concentrations of thyrotropin (less than 2 milli-int. units/L) in their serum.
Ten of these patients had metastatic thyroid cancer, as judged by a positive 1311 whole-body scan (nine of 10 cases), and in some cases by symptoms, palpable lesions, positive chest roentgenogram, or computed tomography scan. The scans and chest roentgenograms for the 10th patient were repeatedly negative, but autopsy (death unrelated) revealed microscopic metastatic papillary thyroid carcinoma in the lungs.
Forty patients were clinically disease free, although one had an 1hI uptake of 0.5% in the thyroid bed, measured 48 h after oral administration of 2.0 mCi of 131j Nineteen (38%) of the 50 sera were found to contain antiTg and thus could be analyzed only by the two IRMA assays.
Group 2 consisted of sera from 70 patients, mostly referrals for whom the corresponding clinical data were not available. As far as we could determine, at least 80% of these sera were also from thyroid-cancer patients, but they included also patients with other thyroid disorders and sera drawn preoperatively from patients evaluated for possible thyroid cancer. These sera were selected by one criterion: they did not contain anti-Tg and thus could be subjected to all three Tg assays.
For linear regression analysis, we replaced Tg values greater than 1000 g/L with the Tg concentrations measured in the same specimens diluted 10-fold. The NMS assay, carried out according to the manufacturer's protocol, produced a standard curve and also results for the two control samples in very good agreement with those stated in the kit literature, indicating to us that we used it properly. However, sera from thyroid cancer patients with high Tg, in the same serial dilutions that exhibited parallelism in the CIS and Stanford assays, gave curves with widely differing slopes, most of them significantly different from the slope of the NMS standard curve (Figure 2) . Similarly, when we used the NMS kit to determine Tg in the CIS kit standards, a displacement curve resulted that did not parallel the NMS standard curve, but was considerably flatter, intersecting the latter in midrange.
Results
Analytical Performance of Assays
A typical standard curve for the Stanford assay is depicted in Figure 3 . Serial dilutions of sera from patients with metastatic thyroid cancer produced indistinguishable curves (13) and analysis by the Stanford assay of the various Tg standard solutions supplied in the CIS or NMS kits gave curves that largely paralleled the Stanford standard curve. Only the least-concentrated standards ( 10 j.g/L) were shifted somewhat to higher Tg values. Serial dilution curves of the most-concentrated NMS standard (500 g/L) or CIS standard (1000 ugfL) in human serum, devoid of Tg, were very similar to the curves obtained with the kit standards, except that they were linear and paralleled the Stanford curve, even in the low range of 3 or 5 gfL.
Mean analytical recovery of Tg added to sera was, by the CIS method, (± ± SD) 92.4 ± 10.0% (range, 80-109%) for the CIS Tg preparation and 91.9 ± 9.8% (range, 87-105%) for the NMS Tg preparation. Recovery in the NMS assay, on the other hand, strongly depended on the Tg preparation and the quantity used; i.e., 92.0% (SD 14.4%, range, 81-125%) of added NMS Tg standard was recovered, but 141.3% (SD 42.3%, range, 100-220%) of the CIS Tg standard. Figure 4 shows results of Tg measurements in 50 patients results ofallher ''I scanswere still negative up tothat date. All three assays were also in agreement in producing positive results (or a positive and a borderline result by the NMS assay) for two other patients who as yet have no positive clinical findings, and gave a negative or borderline Tg result (CIS: < 3; NMS: 5; Stanford: 10 g/L) forone patient with a radioiodine uptake of 0.5%, which was confined to the thyroid bed and which could be due to either a thyroid remnant or recurrent disease.
Correlation between Methods
Clinical Evaluation
The major difference between methods was the percentage of undetectable Tg results, as opposed to low but measurable Tg results, in patients thought to be free of disease.
Using the CIS assay, 34 patients (85%) had undetectable Tg and only three patients with total thyroidectomy and 131j ablation had measurable Tg of 5-10 .tg/L. The Stanford assay gave undetectable Tg in 30 patients (75%) and Tg of 5-10 pg/L in seven patients (two with total thyroidectomy and ''i treatment and five with total or partial thyroidectomy but no 1311). By contrast, the NMS RIA gave undetectable Tg in only 12 (30%) patients without disease, while eiht patients, including five with total thyroidectomy and I, had Tg results of 10 to 15 pg/L.
Discussion
We found the three assays for Tg in serum to differ significantly in methodology, analytical performance, and clinical applicability and usefulness.
Results for Tg by the CIS and Stanford assays correlated well (r = 0.964). The parallelism observed between the Tg standards and serial dilutions of clinical specimens, or analytical recoveries close to those expected theoretically, indicate the high specificity of the antisera used in these two assays (Figures 1 and 3) . The minor differences between these two iaass are primarily related to non-uniformity of the standard concentrations, rendering the CIS results somewhat higher than the Stanford results. The sensitivities of the CIS (3 tg/L) and the Stanford assays (2.5 p.gIL) were also comparable, when one takes into account the differences in the standard concentrations.
On the other hand, the NMS assay gave a weaker correlation with the CIS (r = 0.855) and the Stanford assay (r = 0.888), and the fact that we obtained totally different correlations for the kit standards and patients' sera raises the question of whether these NMS standards are suitable for the interpolation of Tg concentrations in sera. Also, the distinctly different slopes of the various dose-response curves produced by this assay suggest that the NMS antiserum is less specific.
Tg is a large, non-homogeneous protein, which contains many antigenic binding sites. Several forms of Tg with varying iodine content have been isolated. Tg from malignant glands is not necessarily identical with that used to raise antibodies, and repeated freezing and thawing degrades the molecule. Thus, it is plausible that antisera raised in different laboratories against Tg preparations of various degrees of purity or integrity recognize different antigenic determinants and bind different forms of Tg. For instance, an antiserum with high immunoreactivity towards a minor component, a fragment, or other degradation product could explain the several-fold higher Tg values for the NMS standards, as opposed to those for clinical specimens or for other standard preparations.
Differences between the matrices of samples and standards-e.g., the NMS standards contain animal proteins of undisclosed composition-could potentially also cause analytical inaccuracies by interfering with the second-antibody precipitation.
Major matrix-associated problems were ruled CLINICAL CHEMISTRY, Vol. 30, No. 1, 1984 85 out by the fact that dilutions of the highest NMS standard in human Tg-free serum from athyreotic patients produced largely the same dose-response curve as did the kit standards. However, minor matrix effects may account for the deviations in the low range when the CIS or NMS standards were analyzed by the Stanford assay (Figure 3) .
Several studies ( and threepatients had moderately elevated antibody levels (anti-Tg = 80-380 units/mL), so it is possible that some of their Tg results by ms are false negatives. Of more than 100 patients seen at our clinicduring the past years, we have not encountered a single case with low to moderate anti-Tg concentrations where Tg was undetectable but metastatic lesions were large enough to be seen on a whole-body 131j scan. Thus,we assume thatpatients with Tg undetectable by a sensitive reMA, even in conjunction withlowanti-Tg, may notrequire theannual isotope scans.
Differences in the specificity of the antisera may have contributed to some controversy in the literature as to the clinical value of Tg measurements. Two recent studies by Echenique et al. (27) (27) .
In conclusion, our data suggest that the first two commercial assays are not equivalent, and that the clinical utility of Tg measurements will, at least to a certain degree, depend on the assay used. The CIS assay appeared to be more nearly accurate, is more generally applicable for clinical use, and thus will probably have a more beneficial impact on patient care.
